IperionX Rises as Virginia Plant Goes 24/7
IperionX (ASX:IPX) rose 4.66% to A$4.27 on Monday after the company’s March 2026 quarterly report confirmed its Virginia titanium plant is now running 24 hours a day, seven days a week. Production is still in early ramp-up mode, but management is targeting a run-rate of 200 tonnes per annum by the end of 2026, with a 7x expansion to 1,400 tonnes per annum already underway. The 24/7 milestone grabs headlines, but we believe the more important catalyst sits behind it: validation of the company’s next-generation GenX platform later this year.
From Batch to Continuous: Why GenX Is the Real Catalyst
The Virginia plant currently uses IperionX’s HAMR™ process, which produces titanium in batches. GenX™ is the next version of that technology, redesigned to run continuously instead. That may sound technical, but the takeaway for investors is simple. Continuous production almost always costs less per kilogram than batch production, because the plant runs without stops, uses less energy, and delivers more predictable output.
This matters because the global titanium industry has relied on the same expensive Kroll process for roughly 80 years, and that high cost is the main reason titanium remains a niche metal compared to steel or aluminium. If GenX is validated commercially in 2026 as planned, IperionX could end up with one of the lowest titanium cost structures in the world by 2030.
In our view, today’s 24/7 news mostly tells us that execution risk on the Virginia ramp is fading. The real re-rating catalyst still sits ahead.
A Funding Picture Most Small Caps Would Envy
The funding setup is unusually strong for a company at this stage. IperionX closed the March 2026 quarter with US$48.2 million in cash at 31 March and still has more than US$42 million in US Government funding waiting to be drawn down. Most of the cost of expanding capacity to 1,400 tonnes per annum is already covered by US Department of War commitments, and the US Government has even handed over around 290 metric tons of free titanium scrap, enough to feed current production for roughly 1.5 years.
Customer interest is also building. Early orders from defence contractors, including Carver Pump and American Rheinmetall, plus a US Army SBIR Phase III contract with a ceiling of up to US$99 million (paid as the Army places task orders rather than upfront), suggest defence buyers are starting to commit.
The Investors’ Takeaway
The bull case is straightforward. BTIG started coverage in March with a US$40 price target on the NASDAQ-listed shares (roughly A$56 equivalent at current FX), betting that IperionX can replace just 5% of the 40,000-tonne US titanium import market. If the company gets there, today’s price would look cheap.
The bear case deserves equal attention. A short-seller report from November 2025 still weighs on sentiment; GenX has not yet been proved commercially, and the bigger expansion to 1,400 tonnes per annum will not run until mid-2027. There is a long stretch of execution between here and there. In our view, IperionX trades at a clear premium to other speciality metals stocks, but GenX optionality and strong US Government backing justify part of that premium if the 2026 milestones land on time.
